HVAX Technologies Achieves Robust Net Profit Growth of 30% in FY25

Mumbai (Maharashtra) [India], May 19: HVAX Technologies Limited (NSE -HVAX), a turnkey pharmaceutical project integrator specializing in cleanroom infrastructure, HVAC systems, and engineering consultancy, has announced its Audited Financial Results for H2 and FY25.

H2 & FY25 Key Financial Highlights

FY25

  • Total Income of ₹ 131.42 Cr, YoY growth of 22.29%
  • EBITDA of ₹ 18.97 Cr, YoY growth of 31.52%
  • EBITDA Margin (%) of 14.44%, YoY growth of 101 BPS
  • PAT of ₹ 11.04 Cr, YoY growth of 29.69%
  • PAT Margin (%) of 8.40%, YoY growth of 48 BPS
  • EPS of ₹ 45.90, YoY growth of 6.87%

H2 FY25

  • Total Income of ₹ 84.94 Cr
  • EBITDA of ₹ 11.82 Cr
  • EBITDA Margin (%) of 13.92%
  • Net Profit of ₹ 7.22 Cr
  • Net Profit Margin (%) of 8.50%
  • EPS of ₹ 27.20

Commenting on Financial Performance Mr. Nirbhaynarayan Singh, Chairman and Whole-Time Director of HVAX Technologies Limited said: “FY25 has been a transformative and defining year for HVAX Technologies Limited. The period was marked by key milestones, operational progress, and strategic advancements—driven by the company’s commitment to quality, innovation, and long-term value creation.

A major highlight of the year was HVAX’s successful listing on the National Stock Exchange. This milestone enhances the company’s visibility, opens new avenues for growth, and strengthens institutional trust. It also brings greater responsibility, which HVAX is embracing with discipline and a forward-looking mindset.

Internationally, HVAX continued to expand its footprint through repeat orders and new client acquisitions, reinforcing its ability to serve complex and regulated markets. The company also invested in digital systems, process automation, and capacity building to strengthen long-term execution capabilities. HVAX’s teams demonstrated agility and professionalism, enabling the company to consistently exceed client expectations and maintain its leadership position.

Looking ahead, the management remains confident in the company’s strategic direction. Plans are in place to enhance capabilities, explore synergistic partnerships, and deliver sustained value through precision, reliability, and innovation.”

Commenting on Financial Performance, Mr. Prayagdatt Mishra, Managing Director of HVAX Technologies Limited, said: “Our listing on the NSE during FY25 marks a significant milestone for HVAX Technologies, symbolising not only our growth but also our commitment to enhanced transparency and operational discipline. This achievement sets the foundation for the next phase of our expansion.

Throughout the year, we remained focused on delivering integrated, compliant, and technically robust solutions in the cleanroom and controlled environment infrastructure space. We also recorded notable progress in our international business, driven by repeat orders and the addition of new client relationships.

As part of our strategic initiatives, we are exploring collaborations to diversifying industries like healthcare, solar, semiconductors aiming to contribute hugely to their cleanroom-compliant infrastructure. Internally, we continue to strengthen our capabilities through investments in systems, talent, and project planning to meet the evolving demands of regulated sectors.

Looking ahead, our strategy will remain execution-driven and firmly aligned with the industry’s growing need for precision, quality, and reliability.”

If you have any objection to this press release content, kindly contact [email protected] to notify us. We will respond and rectify the situation in the next 24 hours.

aayush jain acquisition Business cashew processing cote d’ivoire esos 2026 pacific global fzco Pajson Agro pulkit jain Royal Mewa Share Swap

From Local to Global: Pajson Agro India to Acquire Pacific Global FZCO, Adding 60,000 MT Capacity at the World’s Largest Cashew Origin

All-stock 100% acquisition | ₹354.52 crore | Board also approves ESOS 2026 New Delhi [India], November 6: Pajson Agro India Limited (PAJSON | 544657 | INE14LM01012), a vertically integrated cashew processing company with farm-gate sourcing across key producing origins and a growing consumer brand, ‘Royal Mewa’, has announced that its Board of Directors, has approved […]

Read More
Business Fredun Pharmaceuticals EBITDA Growth Fredun Pharmaceuticals H1 FY27 Results Fredun Pharmaceuticals Net Profit Fredun Pharmaceuticals Revenue Growth Indian pharmaceutical industry

Fredun Pharmaceuticals On A Growth Overdrive: Net Profit Soars 94%, Ebitda Rockets 92% And Revenue Surges 87% In H1 Fy27

Mumbai (Maharashtra) [India], November 6: Fredun Pharmaceuticals Limited (BSE – FREDUN | 539730), one of India’s leading pharmaceutical formulation manufacturing companies, has announced its unaudited financial results for Q2 & H1 FY27. The Company offers a diversified portfolio spanning generics, cosmeceuticals, nutraceuticals, mobility solutions, and animal healthcare products. Key Financial Highlights Standalone key Financial Highlights […]

Read More
Business

Patil Automation Marks a Strong First Half of FY27; Consolidated Revenue Up 37% YoY, Net Profit Up 48%

Mumbai (Maharashtra) [India], November 6: Patil Automation Limited (NSE: PATILAUTOM | INE17GV01016), a leading provider of turnkey welding, assembly and robotics-integrated automation solutions, has released its Unaudited Standalone and Consolidated Financial Results for the half year ended September 30, 2026, reporting broad-based growth across the group. Performance Snapshot – H1 FY27 H1 FY27 Key Financial […]

Read More